Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma

NCT04380545 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04380545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04380545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 13, 2021
Completion date
February 28, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable fibrolamellar carcinoma